[Inborn and acquired von Willebrand disease].
Von Willebrand disease (VWD) is known for its marked heterogeneity which was already recognized by von Willebrand in 1926. The basis of phenotypic differentiation are quantitative and qualitative or functional differences between the different types and subtypes of VWD. Clinical relevant facts for the practioner on diagnosis and therapy of von Willebrand disease and von Willebrand syndrome are presented.
Schneppenheim
R
R
Klinik für Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg. schneppenheim@uke.de
Budde
U
U
D003894:Deamino Arginine Vasopressin / Q000494:pharmacology; D005169:Factor VIII / Q000502:physiology; D006487:Hemostasis / Q000187:drug effects / Q000502:physiology; D006490:Hemostatics / Q000494:pharmacology; D006801:Humans; D010641:Phenotype; D010974:Platelet Aggregation / Q000187:drug effects; D012310:Ristocetin / Q000494:pharmacology; D014842:von Willebrand Diseases / Q000145:classification / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D014841:von Willebrand Factor / Q000235:genetics / Q000502:physiology*
D006490:Hemostatics; D014841:von Willebrand Factor; D012310:Ristocetin; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin